Navigating Regulatory Barriers For CRISPR Gene Editing Therapies

This content is brought to you by Integrated DNA Technologies, a Danaher Operating Company.

Advancing CRISPR-based therapies from concept to clinic requires more than scientific precision; it demands a clear strategy for navigating complex and evolving regulatory expectations. From early discovery through clinical development, success hinges on aligning study design, manufacturing approaches, and documentation with global agency requirements. Critical considerations such as off-target risk assessment, phase-appropriate materials, and Chemistry, Manufacturing, and Controls (CMC) consistency all play a defining role in regulatory readiness. Real-world progress in personalized gene editing further underscores how streamlined collaboration and regulatory expertise can accelerate timelines. For teams developing next-generation cell and gene therapies, understanding these interconnected steps provides a practical foundation for reducing risk, avoiding delays, and advancing confidently toward approval.

Access the full ebook to gain deeper insights to strengthen your regulatory pathway and bring innovative therapies closer to patients.